First Trust Advisors LP Acquires New Stake in Surgery Partners, Inc. $SGRY

First Trust Advisors LP bought a new position in Surgery Partners, Inc. (NASDAQ:SGRY) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 40,738 shares of the company’s stock, valued at approximately $486,000.

A number of other large investors have also recently added to or reduced their stakes in SGRY. Pentwater Capital Management LP raised its stake in shares of Surgery Partners by 66.9% in the 3rd quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares during the period. UBS Group AG boosted its position in shares of Surgery Partners by 111.4% during the fourth quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after buying an additional 4,113,052 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Surgery Partners by 528.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock worth $30,277,000 after buying an additional 1,647,714 shares in the last quarter. Glenview Capital Management LLC acquired a new stake in Surgery Partners in the 2nd quarter valued at approximately $33,995,000. Finally, Dimensional Fund Advisors LP raised its position in Surgery Partners by 25.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,860,215 shares of the company’s stock valued at $105,177,000 after buying an additional 988,956 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Royal Bank Of Canada cut their target price on Surgery Partners from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a $17.00 price objective on shares of Surgery Partners in a report on Wednesday, May 6th. Benchmark reissued a “buy” rating on shares of Surgery Partners in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price target on shares of Surgery Partners in a research report on Tuesday. Finally, TD Cowen lifted their target price on Surgery Partners from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.45.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Q2 results beat expectations: Adjusted earnings were $0.10 per share versus the $0.06 consensus estimate, while revenue of $848.9 million exceeded the $830.0 million forecast. Revenue increased 2.7% year over year, and same-facility revenue rose 5.0%. Surgery Partners Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year guidance was reaffirmed: Surgery Partners continues to expect 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture. Management said the transaction should improve cash conversion and support deleveraging. Surgery Partners Announces Second Quarter Results
• Positive Sentiment: Analyst support remains favorable: Cantor Fitzgerald reaffirmed its “overweight” rating and set an $18 price target. A separate brokerage consensus target was reported at $21.60, implying substantial potential upside from recent trading levels. Cantor Fitzgerald Reiterates Overweight Rating
• Neutral Sentiment: Broader healthcare stocks could benefit if weak employment data increases expectations for Federal Reserve interest-rate cuts, although this is a sector-wide factor rather than a Surgery Partners-specific catalyst. Likely ETF and Stock Winners From July Jobs Report
• Negative Sentiment: Profitability and cash generation weakened: Q2 net loss attributable to Surgery Partners widened to $15.0 million from $2.5 million a year earlier. Adjusted EBITDA declined to $125.2 million from $129.0 million, while operating cash flow fell to $59.3 million from $81.3 million. Net debt remained elevated at approximately 4.4 times EBITDA. Surgery Partners Reports Second Quarter Results

Surgery Partners Stock Performance

Shares of SGRY opened at $15.00 on Wednesday. The firm has a 50-day moving average of $15.51 and a 200-day moving average of $14.43. Surgery Partners, Inc. has a one year low of $11.41 and a one year high of $24.10. The company has a market cap of $1.96 billion, a PE ratio of -21.43, a price-to-earnings-growth ratio of 4.77 and a beta of 1.91. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.86 and a quick ratio of 1.69.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings data on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The company had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.87%. Surgery Partners’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.17 EPS. As a group, equities analysts forecast that Surgery Partners, Inc. will post 0.25 earnings per share for the current year.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.